A Phase II trial of tandutinib (MLN 518) in combination with bevacizumab for patients with recurrent glioblastoma

CNS Oncology Ahead of Print.


from Cancer via ola Kala on Inoreader http://ift.tt/1Qstu0w
via IFTTT